Scientific studies on neurodegenerative diseases, sleep, and consumer products aim to set new standards for safety, accuracy, and medical potential
DENVER, Feb. 13, 2025 /PRNewswire-PRWeb/ -- MedPharm DBA Bud & Mary's, , continues to lead scientific advancements in cannabis-based therapeutics as the only U.S. company with a DEA Schedule I licensed research facility. With several active studies addressing neurodegenerative diseases such as Alzheimer's, sleep health and product consistency, the company remains at the forefront of industry innovation.
"Our research tackles key challenges in cannabis science, from investigating how cannabinoid-based therapies can treat neurodegenerative diseases to exploring potential benefits for sleep quality and anxiety," said Dr. Duncan Mackie, Director of Pharmacology & Experimental Therapeutics at Bud & Mary's. "By applying rigorous scientific methods and working with leading academic institutions, we are building the data necessary to inform regulatory decisions, guide industry standards, and develop the future of cannabis-based therapeutics."
Bud & Mary's latest research initiatives include:
- Cannabinoids for Alzheimer's Disease: Bud & Mary's research focuses on isolating unique cannabinoids to explore their role in reducing neuroinflammation associated with Alzheimer's disease. Early findings may help regulate the immune system in the brain, potentially reducing neural damage associated with Alzheimer's. This study is laying the groundwork for future cannabinoid-based drug development for neurodegenerative disorders.
- Sleep Clinical Trial with the University of Iowa: A pilot study is underway to assess the effects of a patented, intradermal cannabinoid-based gel on sleep disturbances among adults over 50. Initial data suggests that participants using the gel report improved sleep duration and quality, as well as reductions in nighttime awakenings. The study continues to track long-term effects on sleep and pain management.
- LABeL Research Project: Cannabis Product Label Accuracy: In partnership with the University of Colorado Boulder, Bud & Mary's has independently tested more than 300 retail cannabis products to compare labeled potency claims against actual cannabinoid content. The study identified discrepancies in potency accuracy across different product types, with bulk flower showing the largest variations. Findings suggest systematic inconsistencies between state-licensed testing labs, highlighting the need for standardized testing requirements. The first phase of this study is pending publication in a peer-reviewed journal, with recommendations for regulatory improvements.
This research has produced active patents for Bud & Mary's including Water-Based Extraction and Purification Processes for Cannabinoid Acids; Hybrid Extraction Process for Cannabinoids and Related Methods; Brain Health Formulation; Pharmaceutical Packaging Device; Self-Emulsifying Anhydrous Intradermal Depot Gel; Water Soluble, Powdered Cannabinoid and/or Terpene Extract.
With a DEA Schedule I licensed research facility, an ISO17025-accredited analytical laboratory, and a cGMP and GACP-certified production site, Bud & Mary's is at the forefront of cannabis research. Its efforts include partnerships with Colorado State University Pueblo's Institute of Cannabis Research; University of Colorado's CU-Change; CU Anschutz's Colorado School of Public Health; Northwestern University Feinberg School of Medicine's Department of Physical Medicine & Rehabilitation; Edward Hines Jr. VA Research Service & the Center of Innovation for Complex Chronic Health Care; University of Illinois Chicago Center for Dissemination and Implementation Science; Colorado State University's Department of Psychology; University of Iowa College of Public Health's Cannabis and Older Person Study (COPS) and the Institute for Clinical and Translational Science.
Supporting a broader conversation on evidence-based cannabis research and regulation, Dr. Mackie will speak at UC Anschutz in the Skaggs School of Pharmacy and Pharmaceutical Sciences' Innovation and Entrepreneurship Monthly Seminar Series during the Faculty Forum on Friday, Feb. 21, at 1:30pm. Bud & Mary's will also participate in the First Annual Dinner for the Advancement of Cannabis Science on Tuesday, February 25, supporting a broader conversation on evidence-based cannabis research and regulation. The company's support aligns with its commitment to fostering collaboration between researchers, policymakers, and industry leaders.
For more information on Bud & Mary's research initiatives or to schedule an interview, contact Shawna Seldon McGregor at 917-971-7852 or [email protected].
Bud & Mary's: Crafted for You, Powered by Science.
At Bud & Mary's, we take a science-driven approach to crafting premium cannabis products designed for every individual. From our best-selling BATCH vape cartridges and CURATED flower to our innovative water-soluble TheMyx powder and wellness-focused brands Become and NUO, every product is developed with care, precision, and an unwavering commitment to quality. Locally grown and rigorously tested, Bud & Mary's products meet the highest standards of safety, consistency, and excellence. Through it all, we've remained true to our roots—family-driven, people-focused, and dedicated to pushing the boundaries of cannabis innovation. For more information, visit . Continue the conversation on , , , and .
Media Contact
Shawna Seldon McGregor, Bud & Mary's, 917-971-7852, [email protected],
SOURCE Bud & Mary's
Share this article